摘要
目的评价曲美他嗪对冠心病经皮冠状动脉介入治疗(PCI)术后患者心绞痛的干预作用。方法选择冠状动脉PCI术后再发心绞痛的患者60例,随机分为两组(常规治疗组和曲美他嗪组),进行相关对比研究。结果两组治疗4周后,心绞痛发作频率、持续时间较治疗前均明显减少(P<0.05),曲美他嗪组更为明显,两组间的心率、收缩压、舒张压无差异(P>0.05)。结论加用曲美他嗪联合常规疗法治疗PCI后再发心绞痛的患者能显著减少心绞痛发作次数及发作持续时间,且对血压、心率无影响,无不良反应,是安全、有效、有推广价值的治疗方案。
Objective To evaluate the effect of trimetazidine in coronary heart disease patients after percutaneous coronary intervention. Methods A total of 60 patients treated with PCI were selected randomly to trimetazidine group and routine therapy group for a comparative research. Results Angina frequency, angina duration were all significantly reduced in trimetazidinc group compared to routine therapy group （P 〈 0. 05 ） , there was no significant difference between the two groups （P 〉 0. 05 ） in the heart rate, the systolic blood pressure and the diastolic blood pressure. Conclusion Trimetazidine combined with routine therapy can remarkably reduce angina frequency and angina duration in post PCI patients with coronary heart disease, Therapy with trimetazidine in these patients is safe and available.
出处
《安徽医科大学学报》
CAS
北大核心
2009年第5期615-617,共3页
Acta Universitatis Medicinalis Anhui
基金
安徽省自然科学基金(编号:090413269X)
安徽省卫生厅医学科研课题(编号:09B106)
关键词
曲美他嗪
冠心病
血管成形术
经腔
经皮冠状动脉
trimetazidine
coronary heart disease
angioplasty
transluminal
percutaneous coronary
percutaneous coronary intervention（PCI）
